采用带嵌合抗原受体（CAR）T细胞的养护性细胞免疫疗法已成为治疗复发和/或难治性B细胞非何杰金淋巴瘤（B-NHL）的一种新型疗法。随着CAR T细胞产品的批准和CAR T细胞疗法的进展，预计将在越来越多的病例中使用CAR T细胞。然而，CAR T细胞相关的毒性可能严重甚至致命，从而影响这种疗法所带来的生存益处。规范和研究这些毒性的临床管理是必要的。与其他血液恶性肿瘤（如急性淋巴细胞白血病和多发性骨髓瘤）相比，B-NHL中抗CD19 CAR T细胞相关的毒性具有几个独特的特点，最显著的是局部细胞因子释放综合征（CRS）。然而，先前发布的指南为B-NHL的CAR T细胞治疗相关毒性的分级和管理提供了很少的具体建议。因此，我们根据有关管理抗CD19 CAR T细胞相关毒性的先前文献和多个中国机构的临床经验，制定了这个共识，共识精化了B-NHL的CRS分级系统和分类，并提出了针对CRS的全面治疗原则和探索性建议，并阐述了针对抗CD19 CAR T细胞相关毒性的全面原则和探索性建议。版权所有©2023癌症生物学与医学。

Adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells has emerged as a novel modality for treating relapsed and/or refractory B-cell non-Hodgkin lymphoma (B-NHL). With increasing approval of CAR T-cell products and advances in CAR T cell therapy, CAR T cells are expected to be used in a growing number of cases. However, CAR T-cell-associated toxicities can be severe or even fatal, thus compromising the survival benefit from this therapy. Standardizing and studying the clinical management of these toxicities are imperative. In contrast to other hematological malignancies, such as acute lymphoblastic leukemia and multiple myeloma, anti-CD19 CAR T-cell-associated toxicities in B-NHL have several distinctive features, most notably local cytokine-release syndrome (CRS). However, previously published guidelines have provided few specific recommendations for the grading and management of toxicities associated with CAR T-cell treatment for B-NHL. Consequently, we developed this consensus for the prevention, recognition, and management of these toxicities, on the basis of published literature regarding the management of anti-CD19 CAR T-cell-associated toxicities and the clinical experience of multiple Chinese institutions. This consensus refines a grading system and classification of CRS in B-NHL and corresponding measures for CRS management, and delineates comprehensive principles and exploratory recommendations for managing anti-CD19 CAR T-cell-associated toxicities in addition to CRS.Copyright © 2023 Cancer Biology & Medicine.